StockData
Arvinas, Inc. logo

Arvinas, Inc. (ARVN) stock

ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30
$6.82+0.05 (+0.74%)

Close on Nov 17, 2026Market cap $445.93MP/E 42.6Yield –

Arvinas total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Arvinas's total debt was $500.00K at Jun 30, 2026. For fiscal 2025 it was $600.00K, down 25.0% from the year before. The highest annual figure on record is $2.15M in fiscal 2018.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$600.00K-25.0%
FY2024Dec 31, 2024$800.00K-20.0%
FY2023Dec 31, 2023$1.00M0.0%
FY2022Dec 31, 2022$1.00M0.0%
FY2021Dec 31, 2021$1.00M-50.0%
FY2020Dec 31, 2020$2.00M0.0%
FY2019Dec 31, 2019$2.00M-7.2%
FY2018Dec 31, 2018$2.15M+594.1%
FY2017Dec 31, 2017$310.39K–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$500.00K-28.6%
Q1 FY2026Mar 31, 2026$500.00K-28.6%
Q4 FY2025Dec 31, 2025$600.00K-25.0%
Q3 FY2025Sep 30, 2025$600.00K-25.0%
Q2 FY2025Jun 30, 2025$700.00K-22.2%
Q1 FY2025Mar 31, 2025$700.00K-22.2%
Q4 FY2024Dec 31, 2024$800.00K-20.0%
Q3 FY2024Sep 30, 2024$800.00K-20.0%
Q2 FY2024Jun 30, 2024$900.00K-10.0%
Q1 FY2024Mar 31, 2024$900.00K-10.0%
Q4 FY2023Dec 31, 2023$1.00M0.0%
Q3 FY2023Sep 30, 2023$1.00M0.0%
Q2 FY2023Jun 30, 2023$1.00M0.0%
Q1 FY2023Mar 31, 2023$1.00M0.0%
Q4 FY2022Dec 31, 2022$1.00M0.0%
Q3 FY2022Sep 30, 2022$1.00M0.0%
Q2 FY2022Jun 30, 2022$1.00M0.0%
Q1 FY2022Mar 31, 2022$1.00M-50.0%
Q4 FY2021Dec 31, 2021$1.00M-50.0%
Q3 FY2021Sep 30, 2021$1.00M-50.0%
Q2 FY2021Jun 30, 2021$1.00M-50.0%
Q1 FY2021Mar 31, 2021$2.00M0.0%
Q4 FY2020Dec 31, 2020$2.00M0.0%
Q3 FY2020Sep 30, 2020$2.00M0.0%
Q2 FY2020Jun 30, 2020$2.00M-3.5%
Q1 FY2020Mar 31, 2020$2.00M-5.4%
Q4 FY2019Dec 31, 2019$2.00M-7.2%
Q3 FY2019Sep 30, 2019$2.00M-8.9%
Q2 FY2019Jun 30, 2019$2.07M+567.4%
Q1 FY2019Mar 31, 2019$2.11M–
Q4 FY2018Dec 31, 2018$2.15M–
Q3 FY2018Sep 30, 2018$2.19M–
Q4 FY2017Dec 31, 2017$310.39K–

More Arvinas figures

See a number that looks wrong?